PROLIXIN

Post-LOE

fluphenazine hydrochloride

Bristol Myers Squibb

ANDAORALCONCENTRATE

Approved

Nov 1985

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

PROLIXIN (fluphenazine hydrochloride) by Bristol Myers Squibb is clinical pharmacology fluphenazine hydrochloride has activity at all levels of the central nervous system as well as on multiple organ systems. Approved for the management of manifestations of psychotic disorders. First approved in 1985.

Drug data last refreshed 1w ago

Mechanism of Action

CLINICAL PHARMACOLOGY Fluphenazine hydrochloride has activity at all levels of the central nervous system as well as on multiple organ systems. The mechanism whereby its therapeutic action is exerted is unknown.

Indications (1)

the management of manifestations of psychotic disorders

Company

Worked on PROLIXIN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.